MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation

RELIEF THERAPEUTICS Holding ( (CH:MMTX) ) has issued an update.

MindMaze Therapeutics has detailed a coordinated global reimbursement strategy designed to scale access to its next-generation digital neurorehabilitation therapies and underpin long-term commercial growth. Central to the plan is a U.S. CMS Category III code that reimburses high-intensity, home-based, clinician-supervised digital neurorehabilitation as a service rather than as hardware, marking one of the first reimbursement pathways to recognize AI-driven, remotely supervised neurotherapeutic care at scale. This U.S. framework is complemented by participation in Switzerland’s CHF 11.2 million Innosuisse-backed SwissNeuroRehab flagship consortium to generate national-level clinical and health-economic evidence, and by alignment with NICE digital health evaluation standards in the UK to support future NHS adoption. With more than 27 completed clinical studies, 11 regulatory clearances and a data engine processing over 1.2 billion data points per month, the company positions this integrated reimbursement and evidence-generation approach as a foundation for durable reimbursement, expanded patient access and strengthened competitive standing in AI-powered neurorehabilitation across major healthcare markets.

The most recent analyst rating on (CH:MMTX) stock is a Sell with a CHF2.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:MMTX Stock Forecast page.

More about RELIEF THERAPEUTICS Holding

MindMaze Therapeutics Holding SA, formed in December 2025 through the business combination of Relief Therapeutics Holding SA and NeuroX Group SA, is a Swiss-based, commercial-stage company specializing in evidence-based digital therapeutics for neurological diseases and brain disorders. Leveraging an AI-driven brain technology platform that integrates software, sensors and telehealth, its neurorehabilitation solutions are deployed in clinics and home settings worldwide and target conditions such as stroke, Parkinson’s disease and at-risk aging, while its R&D pipeline is expanding into multiple sclerosis, spinal cord injury, traumatic brain injury and Alzheimer’s disease. The company also manages Relief’s legacy portfolio of biopharmaceutical assets in rare dermatological, metabolic and respiratory diseases and is listed on SIX (MMTX) with U.S. OTC quotations under RLFTF and RLFTY.

Average Trading Volume: 150,927

Technical Sentiment Signal: Strong Sell

Current Market Cap: CHF323.5M

See more data about MMTX stock on TipRanks’ Stock Analysis page.